AEterna Zentaris to Present at Upcoming Scientific and Investment Conferences
September 23 2004 - 8:31AM
PR Newswire (US)
AEterna Zentaris to Present at Upcoming Scientific and Investment
Conferences Data on Perifosine at the Strategic Research
Institute's 2nd Annual Angiogenesis Conference - Corporate Update
at UBS Global Life Sciences Conference QUEBEC CITY, Sept. 23
/PRNewswire-FirstCall/ -- AEterna Zentaris Inc. (TSX: AEZ; Nasdaq:
AEZS) announced today that Dr. Jurgen Engel, Executive Vice-
President, Global Research & Development and Chief Operating
Officer of the Company, will make a presentation on perifosine, an
oral, first-in-class AKT inhibitor currently in Phase II trials for
multiple types of cancer, on Monday, September 27 at 2:45 p.m. ET,
during the Strategic Research Institute's 2nd Annual Angiogenesis
Conference at the Hyatt Regency Cambridge Hotel in Cambridge,
Massachusetts. Furthermore, on Thursday, September 30, Gilles
Gagnon, AEterna Zentaris' President and Chief Executive Officer
will present a corporate update at the UBS Global Life Sciences
Conference at 2:00 p.m. ET, which will be held at the Grand Hyatt
Hotel in New York City. A live webcast of the presentation will be
available on the Company's website at
http://www.aeternazentaris.com/ in the Investors section. A replay
of the webcast will be available through October 30, 2004 at the
same address. About AEterna Zentaris Inc. AEterna Zentaris Inc. is
a biopharmaceutical company focused in oncology and endocrine
therapy. Its extensive portfolio, from drug discovery to marketed
products, includes perifosine, an orally-active AKT inhibitor in
several Phase II trials for multiple cancers, and cetrorelix, an
LHRH antagonist already marketed for in vitro fertilization under
the brand name Cetrotide(R), and also in advanced clinical
development for the treatment of uterine myoma, endometriosis and
benign prostatic hyperplasia (BPH). AEterna Zentaris also owns 62%
of Atrium Biotechnologies Inc., which develops, distributes and
markets active ingredients, specialty fine chemicals, cosmetic and
nutritional products for the cosmetics, chemical, pharmaceutical
and nutritional industries. News releases and additional
information about AEterna Zentaris are available on its new Web
site http://www.aeternazentaris.com/ . Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbor provisions of the U.S. Securities
Litigation Reform Act of 1995. Forward-looking statements involve
known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue
R&D projects, the successful and timely completion of clinical
studies, the ability of the Company to take advantage of business
opportunities in the pharmaceutical industry, uncertainties related
to the regulatory process and general changes in economic
conditions. Investors should consult the Company's quarterly and
annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to
the forward-looking statements. Investors are cautioned not to rely
on these forward-looking statements. The Company does not undertake
to update these forward- looking statements. DATASOURCE: AETERNA
ZENTARIS INC. (FORMERLY/ANCIENNEMENT - LES LABORATOIRES AETERNA
CONTACT: Media Relations, Paul Burroughs, (418) 652-8525, ext. 406,
; U.S. Investor Relations, Lippert/Heilshorn & Associates, Kim
Golodetz, (212) 838-3777, ; Investor Relations, Jacques Raymond,
(418) 652-8525, ext. 360, ; Europe, Matthias Seeber, +49 69 42602
3425, ; To request a free copy of this organization's annual
report, please go to http://www.newswire.ca/ and click on
reports@cnw.
Copyright